Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

Paulina Liberman; Amde Selassie Shifera; Meghan Berkenstock

doi:10.1097/ICO.0000000000002262

Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

Paulina Liberman, Amde Selassie Shifera, Meghan Berkenstock

School of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

PURPOSE: To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis. METHODS: A retrospective small case series. RESULTS: The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation. CONCLUSIONS: The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.

Original language	English (US)
Pages (from-to)	784-786
Number of pages	3
Journal	Cornea
Volume	39
Issue number	6
DOIs	https://doi.org/10.1097/ICO.0000000000002262
State	Published - Jun 1 2020

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/ICO.0000000000002262

Cite this

@article{5f7fb751d8d4471a8c25180c53841e18,

title = "Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis",

abstract = "PURPOSE: To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis. METHODS: A retrospective small case series. RESULTS: The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation. CONCLUSIONS: The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.",

author = "Paulina Liberman and Shifera, {Amde Selassie} and Meghan Berkenstock",

year = "2020",

month = jun,

day = "1",

doi = "10.1097/ICO.0000000000002262",

language = "English (US)",

volume = "39",

pages = "784--786",

journal = "Cornea",

issn = "0277-3740",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

AU - Liberman, Paulina

AU - Shifera, Amde Selassie

AU - Berkenstock, Meghan

PY - 2020/6/1

Y1 - 2020/6/1

N2 - PURPOSE: To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis. METHODS: A retrospective small case series. RESULTS: The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation. CONCLUSIONS: The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.

AB - PURPOSE: To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis. METHODS: A retrospective small case series. RESULTS: The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation. CONCLUSIONS: The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.

UR - http://www.scopus.com/inward/record.url?scp=85084272462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084272462&partnerID=8YFLogxK

U2 - 10.1097/ICO.0000000000002262

DO - 10.1097/ICO.0000000000002262

M3 - Article

C2 - 31985517

AN - SCOPUS:85084272462

SN - 0277-3740

VL - 39

SP - 784

EP - 786

JO - Cornea

JF - Cornea

IS - 6

ER -

Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this